^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ULBP2 expression

    i
    Other names: ULBP2, UL16 Binding Protein 2, RAET1H, Retinoic Acid Early Transcript 1H, UL16-Binding Protein 2, NKG2D Ligand 2, ALCAN-Alpha, NKG2DL2, N2DL2, Retinoic Acid Early Transcript 1L, RAET1L, N2DL-2
    Entrez ID:
    80328
    Associations

    News

    Trials
    1year
    ULBP2 promotes progression of head and neck squamous cell carcinoma by modulating MAPK signaling pathway. (PubMed, J Stomatol Oral Maxillofac Surg)
    We validated that ULBP2 promotes HNSCC cell progression by regulating the MAPK pathway. These findings are crucial for understanding the process of HNSCC pathogenesis and progression caused by ULBP2.
    Journal
    |
    ULBP2 (UL16 Binding Protein 2)
    |
    ULBP2 expression
    1year
    Analysis of the progression of cervical cancer in a low-and-middle-income country: From pre-malignancy to invasive disease. (PubMed, Tumour Virus Res)
    These results will help us elucidate the molecular factors influencing the progression of cervical precancer to cancer. Understanding the risk of progression of specific HPV types and sublineages may aid in the triage of positive patients, and better knowledge of the immune response may aid in developing and applying immunotherapies.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • CCNE1 (Cyclin E1) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD28 (CD28 Molecule) • MELTF (Melanotransferrin) • HLA-E (Major Histocompatibility Complex, Class I, E) • APOBEC3B (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3B) • FOXP3 (Forkhead Box P3) • RUNX3 (RUNX Family Transcription Factor 3) • FLT3LG (Fms Related Receptor Tyrosine Kinase 3 Ligand) • NECTIN2 (Nectin Cell Adhesion Molecule 2) • ULBP2 (UL16 Binding Protein 2)
    |
    IDO1 expression • FOXP3 expression • ULBP2 expression
    over1year
    miR-17-5p/STAT3/H19: A novel regulatory axis tuning ULBP2 expression in young breast cancer patients. (PubMed, Pathol Res Pract)
    This study highlighted the crosstalk between the novel regulatory network composed of miR-17-5p, H19 and STAT3, and their impact on ULBP2 in BC. Moreover, this study underscored the potential role of miR-17-5p in counteracting the immune evasion tactics, particularly the shedding of ULBP2 in young BC patients, through the modulation of the STAT3/H19/ULBP2 regulatory axis. Thus, targeting this novel regulatory network could potentially enhance our understanding and advance the future application of the innate system-mediated immunotherapy in BC.
    Journal • IO biomarker
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • H19 (H19 Imprinted Maternally Expressed Transcript) • MIR17 (MicroRNA 17) • NKG2D (killer cell lectin like receptor K1) • ULBP2 (UL16 Binding Protein 2)
    |
    ULBP2 expression
    2years
    An immune-related prognostic gene ULBP2 is correlated with immunosuppressive tumor microenvironment and immunotherapy in breast cancer. (PubMed, Heliyon)
    Gene Set Enrichment Analysis (GSEA) indicated pathway enrichment in ULBP2 high and low expression groups. In short, this study comprehensively investigated the potential function of ULBP2 in BC, which might make ULBP2 to be an important therapeutic target for BC.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • ULBP2 (UL16 Binding Protein 2)
    |
    ULBP2 expression